SCM
NVAX icon

Suvretta Capital Management’s Novavax NVAX Stock Holding History

Suvretta Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-80,914
Closed -$8.77M – 119
2020
Q3 		$8.77M Buy
+80,914
New +$9.86M 0.16% 55

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Suvretta Capital Management's NVAX Position: Q4 2020 in Review

Suvretta Capital Management sold out of Novavax (NVAX) in Q4 2020, closing a stake of 80,914 shares — an estimated $8.77M sold.

Suvretta Capital Management first reported a position in NVAX in Q3 2020 and held it in 1 quarter. The position peaked at $8.77M in Q3 2020. 347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

  • Suvretta Capital Management reported no remaining Novavax position as of Q4 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 80,914 Novavax shares in Q4 2020, an estimated $8.77M.
  • Suvretta Capital Management first reported a position in Novavax in Q3 2020 and held it in 1 quarter.
  • Suvretta Capital Management's Novavax position peaked at $8.77M in Q3 2020.
  • 347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on Suvretta Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.